PSCH:NSD-PowerShares S&P SmallCap Health Care Portfolio (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 47.82

Change

-1.05 (-2.15)%

Market Cap

USD 0.18B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the S&P SmallCap 600? Capped Health Care Index. The fund generally will invest at least 90% of its total assets in common stocks of small capitalization U.S. healthcare companies that comprise the underlying index. These companies are principally engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies. The fund is non-diversified.

Inception Date: 07/04/2010

Primary Benchmark: S&P Small 600 Cap HealthCare TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.29%

Management Expense Ratio: 0.29 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
CRTTF Cortus Metals Inc 3.20 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

-0.56 (-0.39%)

USD 7.19B
PPH VanEck Pharmaceutical ETF 0.36 %

-0.05 (-0.06%)

USD 0.67B
BBH VanEck Biotech ETF 0.35 %

+0.36 (+0.21%)

USD 0.43B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-0.29 (-0.62%)

USD 0.14B
GNOM Global X Genomics & Biotechnol.. 0.00 %

+0.03 (+0.28%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

-0.07 (-0.23%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

-0.29 (-1.93%)

USD 0.01B

ETFs Containing PSCH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.73% 75% C 65% D
Dividend Return 0.24% 40% F 3% F
Total Return 11.97% 75% C 63% D
Trailing 12 Months  
Capital Gain 28.34% 75% C 69% C-
Dividend Return 0.28% 33% F 2% F
Total Return 28.63% 75% C 68% D+
Trailing 5 Years  
Capital Gain 21.66% 38% F 60% D-
Dividend Return 0.27% 29% F 1% F
Total Return 21.93% 38% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 1.90% 50% F 44% F
Dividend Return 1.93% 50% F 40% F
Total Return 0.02% 38% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 31.17% 50% F 60% D-
Risk Adjusted Return 6.18% 38% F 39% F
Market Capitalization 0.18B 63% D 47% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.